Preserve Muscle During Weight Loss? Regeneron’s COURAGE Trial Suggests a New Path with Antibody Therapy
New interim data reveals a way to counter muscle loss caused by semaglutide—Regeneron’s antibody combinations may offer a smarter weight-loss strategy focused on body composition.
Table of Contents
Regeneron’s Phase 2 COURAGE Trial: A New Strategy for Muscle-Sparing Weight Loss
The Challenge
What the COURAGE Trial Tested
- Population: Adults with obesity (BMI ≥ 30 kg/m²)
- Treatments (Phase 1, Weeks 0–26): Semaglutide alone; Semaglutide + trevogrumab, low or high dose (anti‑GDF8/myostatin); Triplet combo: Semaglutide + high-dose trevogrumab + garetosmab (anti‑activin A)
- Endpoints: At Week 26, evaluated percent change in body weight, lean mass, and fat mass via DXA (dual-energy X-ray absorptiometry).
Interim Results from Week 26
Semaglutide Alone
- Total Weight Loss: 23 lb
- Lean Mass Loss: 34.5% (~7.9 lb)
- Fat Mass Loss: 66.3%
Low-Dose Combo (Semaglutide + Low Trevogrumab)
- Total Weight Loss: 21.6 lb
- Lean Mass Loss: ~17% (~3.7 lb)
- Fat Mass Loss: 78.1%
- Lean Mass Preserved: ~50.8% vs semaglutide alone
High-Dose Combo (Semaglutide + High Trevogrumab)
- Total Weight Loss: 24.8 lb
- Lean Mass Loss: ~16.8% (~4.2 lb)
- Fat Mass Loss: 76.3%
- Lean Mass Preserved: ~51.3% vs semaglutide alone
Triplet Combo (Semaglutide + High Trevogrumab + Garetosmab)
- Total Weight Loss: 30 lb
- Lean Mass Loss: ~6.6% (~2.0 lb)
- Fat Mass Loss: 84.4%
- Lean Mass Preserved: ~80.9% vs semaglutide alone
Key insight: All combo treatments preserved significantly more lean mass and enhanced fat loss compared to semaglutide alone. The triplet group showed the strongest effect: muscle preservation of ~81% and greatest fat reduction.
Safety Signals
- General tolerability: Semaglutide + trevogrumab was similar to semaglutide alone.
- Triplet arm: Higher adverse events—28.3% discontinued, ~10% experienced severe treatment-emergent adverse events (TEAEs), including two deaths (one from cardiac arrest; no causal link established).
Why Muscle-Sparing Matters
Weight loss is only part of the story. For patients using semaglutide, a significant portion of that weight—up to 35%—can come from lean muscle. That’s not just a cosmetic concern; it’s a risk to strength, mobility, metabolic health, and long-term wellbeing.
Regeneron’s COURAGE trial offers a glimpse into a new approach: combining semaglutide with targeted antibodies to protect muscle while enhancing fat loss. Rather than settling for a lower number on the scale at the cost of strength and function, this approach opens the door to smarter, more targeted weight-loss outcomes.
Here’s what stands out:
- More providers are recognizing that how patients lose weight is just as important as how much they lose.
- The COURAGE trial addresses a persistent issue with GLP-1 therapies: unintended muscle loss.
- The study explores a novel co-therapy model where antibody-based treatments (trevogrumab and garetosmab) are layered onto semaglutide.
- Results suggest this strategy significantly boosts fat loss while protecting lean mass, improving both health outcomes and patient satisfaction.
- If confirmed safe and sustainable, this approach may reshape the standard of care for obesity—focusing on composition, not just pounds lost.
Key Takeaways for Providers
- Semaglutide alone: About 35% of weight lost is lean mass, which may undermine functional outcomes.
- Adding antibodies: Trevogrumab (anti-myostatin) with or without garetosmab (anti-activin A) preserved 51–81% more muscle and increased fat loss.
- Best balance: The triplet combo was most effective but had more safety concerns. Dual antibody regimens may offer the best balance of efficacy and safety.
- What’s next: Final phase 2 data will include results from the maintenance phase (weeks 26–52).
Who Could Benefit
- Patients on GLP-1 receptor agonists struggling with unintended muscle loss
- Individuals seeking more functional or metabolic benefits from weight loss
- Providers concerned about sarcopenia or frailty during obesity treatment
What Comes Next
- Monitor publication of full 52-week COURAGE trial data
- Evaluate long-term outcomes on both body composition and adverse events
- Prepare to integrate antibody therapies into future obesity protocols—if confirmed safe and effective
Conclusion
The interim findings from Regeneron’s COURAGE trial underscore a pivotal shift in how we think about weight loss—moving beyond just the number on the scale.
By prioritizing fat loss while preserving lean muscle, this antibody-supported approach could set a new standard for safer, more functional weight reduction.
While questions about long-term safety remain, the potential to improve patient outcomes by focusing on composition, not just weight, is worth watching as the full trial data emerges.
GLP-1 Certification for Weight Loss
Get trained in glp-1s and FDA-approved medical weight management treatments. Learn from the comfort of your home or office with our comprehensive online Certified Medical Weight Management Provider™ (CWMP) program.
